Design of the MIST study: a double-blind, randomised, placebo-controlled phase 2b trial of pirfenidone solution for inhalation in patients with progressive pulmonary fibrosis

Martin Kolb, Tamera J Corte, Jeremy Feldman, Steven D Nathan, Colin Reisner, Deepthi Nair, Felix Woodhead, Howard Lazarus, Craig Conoscenti · 2025

Read Design of the MIST study: a double-blind, randomised, placebo-controlled phase 2b trial of pirfenidone solution for inhalation in patients with progressive pulmonary fibrosis by Martin Kolb, Tamera J Corte, Jeremy Feldman, Steven D Nathan, Colin Reisner, Deepthi Nair, Felix Woodhead, Howard Lazarus, Craig Conoscenti (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12742111.txt.

Description

Martin Kolb and colleagues designed a lung fibrosis trial in two thousand twenty-five. The MIST study tests an inhaled drug solution. Progressive lung scarring affects patients beyond the classic type. Swallowed pirfenidone helped little in earlier small studies. Heavy body exposure caused substantial side effects. Inhaling the drug may improve tolerability.

About three hundred patients will join worldwide. Groups receive high dose, low dose, or placebo. A special nebulizer delivers treatment twice daily. Lung capacity change after one year is the main measure. Quality of life and disease progression are also tracked. The double-blind design keeps assessments fair. Results should settle the inhaled approach's value.

Catalog record

CREATORMartin Kolb, Tamera J Corte, Jeremy Feldman, Steven D Nathan, Colin Reisner, Deepthi Nair, Felix Woodhead, Howard Lazarus, Craig Conoscenti
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE60 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12742111

Browse the full library · About the Tower of Babel